Ezetimibe: Use, costs, and adverse events in Australia
ConclusionsEzetimibe use has increased rapidly in Australia since receiving public subsidy. Although the indications for subsidy are very restricted, there appears to have been widespread use, not explained by differential geographical IHD death rates. Latest guidelines still question the value of ezetimibe, so further discussion about whether the public spending on this medication for any potential improvement in population health outcomes is justified.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Samantha A. Hollingworth, Remo Ostino, Michael C. David, Jennifer H. Martin, Susan E. Tett Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Gastroenterology | Heart | Heart Disease | Medicare | Simvastatin | Statin Therapy | Vytorin | Zetia | Zocor